Payment overview · 2025
General Payments
$293.44
17 reported records · 10 companies
Healthcare provider profile · identity verified
Ryan John Gleesing, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLINTON TOWNSHIP, MI · NPI 1851688139
Verified facts
What the public records show
CMS Open Payments records show Ryan John Gleesing, D.O. received $293.44 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.01 | 25.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.10 | 16.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.46 | 11.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.23 | 11.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.24 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.75 | 5.7% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.15 | 5.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.77 | 5.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.38 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.35 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $293.44 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.00 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.95 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.95 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.95 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 105 |
| Lisinopril | Lisinopril | 238 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 51 |
| Losartan Potassium | Losartan Potassium | 187 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 21 |
| Omeprazole | Omeprazole | 140 | 41 |
| Alprazolam | Alprazolam | 139 | 31 |
| Simvastatin | Simvastatin | 133 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 35 |
| Metformin Hcl | Metformin Hcl | 105 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 37 |
| Furosemide | Furosemide | 104 | 41 |
| Montelukast Sodium | Montelukast Sodium | 77 | 22 |
| Gabapentin | Gabapentin | 76 | 19 |
| Prednisone | Prednisone | 74 | 62 |
| Sertraline Hcl | Sertraline Hcl | 74 | 23 |
| Meloxicam | Meloxicam | 73 | 20 |
| Methylprednisolone | Methylprednisolone | 68 | 57 |
| Lorazepam | Lorazepam | 67 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 57 |
| Allopurinol | Allopurinol | 65 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 19 |
| Famotidine | Famotidine | 57 | 23 |
| Baclofen | Baclofen | 53 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 20 |
| Tramadol Hcl | Tramadol Hcl | 51 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 16 |
| Lovastatin | Lovastatin | 48 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 12 |
| Potassium Chloride | Potassium Chloride | 43 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 15 |
| Eliquis | Apixaban | 39 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 31 |
| Chlorthalidone | Chlorthalidone | 36 | 11 |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Ozempic | Semaglutide | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 14 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 20 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 12 |
| Azithromycin | Azithromycin | 24 | 22 |
| Carvedilol | Carvedilol | 23 | 11 |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Ondansetron Odt | Ondansetron | 23 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 15 |
| Glipizide | Glipizide | 18 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Benzonatate | Benzonatate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $293.44 · 17 records | Amgen Inc. | ABRYSVO, COMIRNATY, EVENITY, General - Pain Management, Heplisav-B, INCEPTIV, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Veozah, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error